Waters 향후 성장

Future 기준 점검 2/6

Waters (는) 각각 연간 14.3% 및 6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 13.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 22.7% 로 예상됩니다.

핵심 정보

14.3%

이익 성장률

13.58%

EPS 성장률

Life Sciences 이익 성장	17.6%
매출 성장률	6.0%
향후 자기자본이익률	22.68%
애널리스트 커버리지	Good
마지막 업데이트	23 Dec 2025

최근 향후 성장 업데이트

Recent updates

Waters Merger Risks Weakening Its Competitive Moat

Sep 29

Risks To Shareholder Returns Are Elevated At These Prices For Waters Corporation (NYSE:WAT)

Sep 19

Waters Corporation: Instrument Replacement Cycle Momentum, But Valuation Is A Concern

Feb 21

Waters Corporation's (NYSE:WAT) Share Price Could Signal Some Risk

Feb 01

Weighing In On Waters Corporation: Facing A Valuation Headwind

Jan 29

Should You Investigate Waters Corporation (NYSE:WAT) At US$377?

Dec 27

Waters Corp: Short Reinvestment Runway Diminishes High Multiples

Nov 13

Waters Corp.: Embedded Expectations High Under Present Conditions

Aug 15

Waters Corporation: Still Struggling A Bit

May 24

Waters Corporation: A Great (Share Price) Run

Mar 11

Waters Corporation: High Quality Niche Company In Mass Spectrometry

Dec 28

Waters Corporation: Appealing Levels Are Offset By Weaker Performance

Nov 13

Waters Corporation: Buybacks Ceased, Incremental Returns Languishing (Rating Downgrade)

Sep 27

Waters Corporation: Temporary Headwinds Present A Buying Opportunity

Jul 18

이익 및 매출 성장 예측

NYSE:WAT - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	3,572	860	954	1,070	9
12/31/2026	3,360	823	863	993	13
12/31/2025	3,162	680	649	781	15
9/27/2025	3,106	649	602	728	N/A
6/28/2025	3,046	661	619	745	N/A
3/29/2025	2,983	657	619	759	N/A
12/31/2024	2,958	638	620	762	N/A
9/28/2024	2,905	623	620	752	N/A
6/29/2024	2,877	596	561	705	N/A
3/30/2024	2,909	604	514	669	N/A
12/31/2023	2,956	642	442	603	N/A
9/30/2023	2,995	653	390	571	N/A
7/1/2023	2,992	675	387	572	N/A
4/1/2023	2,966	689	425	610	N/A
12/31/2022	2,972	708	428	612	N/A
10/1/2022	2,950	697	465	631	N/A
7/2/2022	2,901	702	477	641	N/A
4/2/2022	2,868	705	565	727	N/A
12/31/2021	2,786	693	579	747	N/A
10/2/2021	2,736	695	626	797	N/A
7/3/2021	2,671	660	642	802	N/A
4/3/2021	2,509	616	697	857	N/A
12/31/2020	2,365	522	618	791	N/A
9/26/2020	2,295	504	536	715	N/A
6/27/2020	2,278	515	495	691	N/A
3/28/2020	2,358	537	430	619	N/A
12/31/2019	2,407	592	479	643	N/A
9/28/2019	2,405	577	491	633	N/A
6/29/2019	2,406	580	N/A	631	N/A
3/30/2019	2,403	591	N/A	604	N/A
12/31/2018	2,420	594	N/A	604	N/A
9/29/2018	2,392	55	N/A	615	N/A
6/30/2018	2,380	51	N/A	623	N/A
3/31/2018	2,342	27	N/A	699	N/A
12/31/2017	2,309	20	N/A	698	N/A
9/30/2017	2,251	548	N/A	679	N/A
7/1/2017	2,212	537	N/A	674	N/A
4/1/2017	2,190	533	N/A	656	N/A
12/31/2016	2,167	522	N/A	643	N/A
10/1/2016	2,125	498	N/A	623	N/A
7/2/2016	2,099	490	N/A	613	N/A
4/2/2016	2,057	467	N/A	567	N/A
12/31/2015	2,042	469	N/A	573	N/A
10/3/2015	2,040	469	N/A	568	N/A
7/4/2015	2,032	467	N/A	557	N/A
4/4/2015	2,019	457	N/A	550	N/A
12/31/2014	1,989	432	N/A	512	N/A

애널리스트 향후 성장 전망

수입 대 저축률: WAT 의 연간 예상 수익 증가율(14.3%)이 saving rate(3.3%)보다 높습니다.

수익 vs 시장: WAT 의 연간 수익(14.3%)이 US 시장(16.2%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: WAT 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: WAT 의 수익(연간 6%)이 US 시장(연간 10.7%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: WAT 의 수익(연간 6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: WAT의 자본 수익률은 3년 후 22.7%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/26 01:28
종가	2025/12/24 00:00
수익	2025/09/27
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Waters Corporation는 37명의 분석가가 다루고 있습니다. 이 중 15명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Catherine Ramsey Schulte	Baird
Luke Sergott	Barclays
Charles Butler	Barclays

Waters 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 7.6% to US$383

Waters Corporation Raises Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2025

Price target decreased by 7.2% to US$347

Waters Corporation Raises Earnings Guidance for the Full Year 2025

Waters Corporation Provides Earnings Guidance for the Second Quarter Ending June 28, 2025 and Full Year Ending December 31, 2025

Waters Corporation Provides Earnings Guidance for the First Quarter of 2025 and Full Year 2025

Recent updates

Waters Corporation Boosts Lab Productivity and Sample Throughput with Launch of Its Charged Aerosol Detector Designed for Empower Software

Price target increased by 7.6% to US$383

Waters Corporation Raises Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2025

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Waters Corporation to Report Q3, 2025 Results on Nov 04, 2025

Waters Merger Risks Weakening Its Competitive Moat

Risks To Shareholder Returns Are Elevated At These Prices For Waters Corporation (NYSE:WAT)

Price target decreased by 7.2% to US$347

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Waters Corporation Raises Earnings Guidance for the Full Year 2025

Are Investors Undervaluing Waters Corporation (NYSE:WAT) By 36%?

Investor sentiment deteriorates as stock falls 17%

Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion.

These 4 Measures Indicate That Waters (NYSE:WAT) Is Using Debt Reasonably Well

Waters Corporation (NYSE:WAT) acquired Halo Labs.

Now 22% undervalued after recent price drop

Waters Corporation (NYSE:WAT) acquired Optofluidics, Inc.

Waters Corporation's (NYSE:WAT) Shares May Have Run Too Fast Too Soon

First quarter 2025 earnings released

Now 21% undervalued after recent price drop

Waters Corporation Provides Earnings Guidance for the Second Quarter Ending June 28, 2025 and Full Year Ending December 31, 2025

Is Waters Corporation (NYSE:WAT) Trading At A 24% Discount?

Waters Corporation, Annual General Meeting, May 22, 2025

Waters Expands Alliance iS Bio HPLC Product Line with Photodiode Array Detector to Enhance Spectral Insights for Biopharma Development & QC

Waters Corporation: Instrument Replacement Cycle Momentum, But Valuation Is A Concern

Waters Corporation Provides Earnings Guidance for the First Quarter of 2025 and Full Year 2025

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Waters Corporation's (NYSE:WAT) Share Price Could Signal Some Risk

Weighing In On Waters Corporation: Facing A Valuation Headwind

Should You Investigate Waters Corporation (NYSE:WAT) At US$377?

Waters Corp: Short Reinvestment Runway Diminishes High Multiples

Price target increased by 7.5% to US$375

Waters Corporation Raises Earnings Guidance for the Full Year of Fiscal Year Ending December 31, 2024

Second quarter 2024 earnings released: EPS: US$2.41 (vs US$2.56 in 2Q 2023)

Investor sentiment improves as stock rises 19%

Waters Corporation Provides Earnings Guidance for the Fourth Quarter Ending December 31, 2024

Now 20% undervalued

Waters Corporation Announces New Bioseparations Tools Accelerate and Improve Development of Rna-Based Vaccines and Therapies Using LC-MS Analysis

Waters Corporation Introduces TA Instruments Discovery Core Rheometer

Now 20% undervalued

Waters Corp.: Embedded Expectations High Under Present Conditions

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Waters Corporation to Report Q2, 2024 Results on Jul 31, 2024

Waters Corporation New Rapid Screening-DSC Enables Up to 24x Faster Thermal Stability Testing at Ultra-Low Sample Volumes for Antibody Drugs

Now 20% undervalued after recent price drop

Waters Corporation: Still Struggling A Bit

Independent Director notifies of intention to sell stock

Waters Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024

First quarter 2024 earnings: EPS misses analyst expectations

Waters Corporation Accelerates the Development of Gene-Based Therapeutics with New GTxResolve Premier SEC Columns

Waters Corporation, Annual General Meeting, May 23, 2024

Waters Corporation: A Great (Share Price) Run

Price target increased by 7.8% to US$323

Waters Corporation Provides Earnings Guidance for the First Quarter and Full-Year 2024

Waters Corporation: High Quality Niche Company In Mass Spectrometry

Waters Corporation: Appealing Levels Are Offset By Weaker Performance

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Waters Corporation Announces Resignation of Jonathan Pratt as Senior Vice President of the Waters Division

Waters Corporation Launched OligoWorks SPE Workflow and Kits

Waters Corporation: Buybacks Ceased, Incremental Returns Languishing (Rating Downgrade)

Waters Corporation Introduces DynaPro™? ZetaStar™? Instrument from its Wyatt Technology™? Portfolio for Nanoparticle Analysis

Independent Director notifies of intention to sell stock

Waters Corporation Provides Earnings Guidance for the Third Quarter and Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Waters Corporation Launches XBridge Premier GTx BEH SEC Columns for Gene Therapy Applications

Waters Corporation: Temporary Headwinds Present A Buying Opportunity

Waters Corporation Boosts Resolution and Triples Scan Speed of Select Series MRT for Metabolomics and MS Imaging

Price target decreased by 9.9% to US$311